Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2581 to 2595 of 8235 results

  1. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

    Quality standard
    In development

  2. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development Reference number: GID-TA11036 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Clindamycin for treating bacterial vaginosis in females aged 12 and older [TSID 12127]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Risankizumab for treating moderate to severe plaque psoriasis in people 6 to 17 years [TSID12204]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. AI in retinal scanning MT524 (MIB265)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. PROPEL (mometasone furoate implant, 370ug) MT578 (MIB253)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. MTEP - Routing Butterfly IQ ultrasound scanner MT635 (MIB254)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Kodex EPD system MT575 (MIB260)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation